NCT04172779View on ClinicalTrials.gov

Erlotinib for Hepatocellular Carcinoma Chemoprevention

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2030

Conditions
Cirrhosis, Liver
Interventions
DRUG

Erlotinib Hydrochloride

Oral administration of erlotinib 25mg tablet

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Texas Southwestern Medical Center

OTHER